Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncolytic herpes simplex virus for tumor therapy

Jennifer C C Hu1, Robert S Coffin

  • 1Cancer Cell Biology, Hammersmith Hospital Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom.

International Review of Neurobiology
|September 13, 2003
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Journal for immunotherapy of cancer·2026
Same author

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.

Journal for immunotherapy of cancer·2020
Same author

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Journal for immunotherapy of cancer·2019
Same author

White paper on microbial anti-cancer therapy and prevention.

Journal for immunotherapy of cancer·2018
Same author

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.

Oncolytic virotherapy·2016